Opus biotech communications
WebOpus Biotech Communications offers a wide range of communications and consulting services especially designed for emerging companies that have compelling stories to tell to investors, potential partners and the media, but have limited resources. Opus Biotech principals have been leaders in the biotech revolution since its beginnings. WebMedPoint Digital, Inc. provides digital communications and Web-based systems for pharmaceutical and biotechnology companies in the United States. The company offers …
Opus biotech communications
Did you know?
WebDec 5, 2024 · Contacts Opus Biotech Communications Dan Eramian, +1-425-306-8716 [email protected] Release Summary Lumen Biosciences introduces new, breakthrough biotech product platform Contacts... WebOpus Biotech Communications Daniel Eramian 425-306-8716 [email protected] Charles Craig 404-245-0591 [email protected]. Home About Technology Development News & Publications Contact.
WebAug 18, 2024 · For Chicago’s many life sciences organizations, helping people live their healthiest lives is key to bolstering the city’s biotech community. Take a look at these 15 … WebOpus Biotech Communications LLC Company Profile Decatur, GA Competitors, Financials & Contacts - Dun & Bradstreet. Find company research, competitor information, contact …
WebMar 23, 2024 · Opus Biotech Communications [email protected] 425-306-8716. Charles Craig Opus Biotech Communications [email protected] 404-245-0591. On December 29, 2024 / NanOlogy Press Release Recent Nanology News. WebApr 26, 2024 · Opus Biotech Communications, a life sciences public affairs and investor relations consultancy based in Seattle with branches in Atlanta, Newport Beach and San …
WebSep 12, 2024 · Opus Biotech Communications Dan Eramian, 425-306-8716 [email protected] or Opus Biotech Communications Charles Craig, 404-245-0591 [email protected]. Release Summary.
WebDec 3, 2024 · Opus Biotech Communications [email protected] 425-306-8716. SOURCE Nanoscope Therapeutics. ioof portfolio superannuation fundWebC0-Founder at Opus Biotech Communications. 6mo Report this comment Report Report. Back Submit. Jeff, big congrats! Like Reply 1 Reaction 2 ... on the market hayleWebApr 4, 2024 · The company's pipeline includes therapies for RP, Stargardt, other Inherited Retinal Degenerations, and Geographic Atrophies. For more information visit: … ioof portfolio oneWebJun 3, 2024 · The company’s pipeline includes vision restoration in patients with retinitis pigmentosa, Stargardt disease, and age-related macular degeneration. More information about Nanoscope Therapies Contact: Charles Craig Opus Biotech Communications [email protected] 404-245-0591 On June 3, 2024 / Nanoscope Press Release, … ioof platformWebJan 25, 2024 · The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with RP, Stargardt, and dry age-related MD. Contact: Dan Eramian Opus Biotech Communications [email protected] 425-306-8716 On January 25, 2024 / Nanoscope Press Release, Home Page Nanoscope In The News ioof portfolioWebBiotechnology. Headquarters Regions Washington DC Metro Area, East Coast, Southern US. Founded Date 2004. Operating Status Active. Also Known As Lentigen. Company Type For … ioof portfolio service allocated pensionWebMar 5, 2024 · BEDFORD, Texas, March 5, 2024 /PRNewswire/ — Researchers of Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal diseases, ... Opus Biotech Communications [email protected] 404-245-0591. On March 5, ... ioof portfolio service investments